Form 4: Coherus Director Ali J. Satvat Awarded Equity Grants

Director Ali J. Satvat received 30,000 restricted stock units and 60,000 stock options as part of annual compensation for service on the board.

Summary

• Ali J. Satvat, a Director at Coherus Oncology, was granted 30,000 restricted stock units (RSUs) on June 5, 2026.
• The reporting person also received 60,000 stock options with an exercise price of $1.45 per share.
• Both the RSUs and the stock options are scheduled to vest 100% on June 3, 2027, contingent on continued service.
• The stock options have a ten-year term, expiring on June 5, 2036.
• Following these transactions, the director holds a total of 90,000 derivative and non-derivative securities from this grant cycle.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative event. While it aligns director interests with shareholders, it is a standard part of compensation and does not signal a change in company fundamentals.

Positives

• Aligns director interests with those of shareholders through equity-based compensation.
• The 100% cliff vesting in June 2027 incentivizes director retention for the next year.
• The exercise price of $1.45 sets a clear baseline for value creation for the options.

Negatives

• The issuance of 90,000 potential shares contributes to the overall dilution of existing shareholders.
• The awards have no immediate value and are subject to market volatility and company performance.

Risks

• The value of the 60,000 options is entirely dependent on the stock price exceeding $1.45 by the time of exercise.
• Vesting is subject to the director's continued service relationship, posing a risk of forfeiture if the director leaves the board before June 3, 2027.

Future Outlook

The grants indicate a standard annual compensation structure for the board of directors, suggesting stability in corporate governance through the mid-2027 period.

Management Comments

• The RSUs and options vest on the one-year anniversary of June 3, 2026, subject to continued service.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is a standard practice in the biotechnology sector to preserve cash reserves while ensuring board members are incentivized to drive long-term share price appreciation.

Comparison to Industry Standards

• The grant size of 90,000 total units is consistent with equity awards for directors at mid-cap biotechnology firms.
• The use of a one-year cliff vest is a common industry standard for annual director equity grants.
• The ten-year option term is typical for incentive stock options in the U.S. market.

Related Party Transactions

• The issuance of equity to a director is a related party transaction conducted under the company's incentive compensation plan.

Stakeholder Impact

• Shareholders may experience minor dilution upon the future vesting and exercise of these securities.
• The board's continuity is supported by the multi-year vesting schedule.

Next Steps

• Vesting of 30,000 RSUs on June 3, 2027.
• Vesting of 60,000 stock options on June 3, 2027.

Key Dates

Recommendation

This filing covers routine director compensation and does not provide new material information regarding the company's clinical pipeline or financial performance that would warrant a change in investment thesis.

Keywords

Coherus Oncology, CHRS, Insider Trading, Form 4, Director Compensation, Stock Options, Restricted Stock Units, Ali J. Satvat, Biotechnology